Researchers recommend ‘caution’ when using the chemotherapy busulfan in patients with Gilbert’s syndrome
Oct. 27, 2016
| By Susan Keown / Fred Hutch News Service
As many as one of every 10 people has Gilbert's syndrome, which is typically benign and has even been linked to long life. But new research suggests that busulfan, a bone marrow transplant drug, is extra risky in people with the condition.
New risk prediction model — not yet ready for clinical use — incorporates genetic, lifestyle and environmental risk factors
April 18, 2016
| By Rachel Tompa / Fred Hutch News Service
In work presented Monday at the American Association for Cancer Research’s annual meeting in New Orleans, researchers from Fred Hutch, the University of Michigan and other institutes debuted their latest progress in precision prevention — an in-the-works method to predict risk of colorectal cancer that integrates genetic, lifestyle and environmental risk factors.
Fred Hutch is proud to be an Equal Opportunity and VEVRAA Employer. We are committed to cultivating a workplace in which diverse perspectives and experiences are welcomed and respected. We do not discriminate on the basis of race, color, religion, creed, ancestry, national origin, sex, age, disability, marital or veteran status, sexual orientation, gender identity, political ideology, or membership in any other legally protected class. We are an Affirmative Action employer. We encourage individuals with diverse backgrounds to apply and desire priority referrals of protected veterans. Read the EEO is the Law poster here.